PAD4 inhibitor, preparation method thereof and application of PAD4 inhibitor in preparation of anti-pulmonary fibrosis drugs

By designing and synthesizing the new PAD4 inhibitor RC2-33, the problem of insufficient activity of PAD4 inhibitors in the prior art was solved, effective inhibition of PAD4 was achieved, slowed the process of pulmonary fibrosis, and provided by atomization and inhalation Anti-pulmonary fibrosis treatment effect.

CN118908874AActive Publication Date: 2024-11-08CAPITAL UNIVERSITY OF MEDICAL SCIENCES

Patent Information

Application Number
CN202410943246.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-15
Publication Date
2024-11-08
Estimated Expiration
2044-07-15

AI Technical Summary

Technical Problem

The existing PAD4 inhibitors have poor inhibitory activity on PAD4 enzymes and cannot effectively inhibit the formation of extraneutrophilic traps (NETs), making it difficult to control the pulmonary fibrosis process.

Method used

A new PAD4 inhibitor, RC2-33, was designed, which reacts a series of condensation and protecting groups with specific compounds through biphenyl-3-carboxylic acid, and is ultimately substituted with 2-chloroacetimidine ethyl ester hydrochloride The reaction is to form a small molecule compound that effectively inhibits PAD4 activity and is applied to anti-pulmonary fibrosis treatment through atomization and inhalation.

Benefits of technology

RC2-33 can significantly reduce histone citrulline, inhibit the formation of NETs, ​​prevent the activation and transformation of lung fibroblasts, slow down the progression of lung fibrosis, and improve the inflammation and fibrosis status of mice.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118908874A_ABST
    Figure CN118908874A_ABST
Patent Text Reader

Abstract

The invention provides a PAD4 inhibitor, a preparation method thereof and application of the PAD4 inhibitor in preparation of anti-pulmonary fibrosis drugs, and belongs to the technical field of biological medicines. According to the invention, PAD4 is used as a new target for treating pulmonary fibrosis, and structural modification is carried out on chloramidine to obtain the PAD4 inhibitor with the structure as shown in the formula I. The small-molecule inhibitor can inhibit the activity of PAD4, reduce formation of NETs, inhibit activation of lung fibroblasts and conversion of lung fibroblasts into myofibroblasts, reduce lung collagen deposition and slow down the pulmonary fibrosis process. In vitro, RC2-33 can reduce histone citrullination, inhibit formation of NETs, inhibit proliferation of lung fibroblasts induced by TGF-beta1, and down-regulate interstitial marker proteins such as alpha-SMA, COL-I, FN-I and the like. The aerosol inhalation of RC2-33 can effectively reduce the formation of NETs in the lung of a mouse, inhibit the transformation of epithelial cells to interstitial cells, reduce extracellular matrix deposition and improve the pulmonary fibrosis of the mouse.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomedicine, and in particular to a PAD4 inhibitor and a preparation method thereof and application thereof in the preparation of an anti-pulmonary fibrosis drug. Background Art

[0002] Pulmonary fibrosis is an interstitial lung disease with a long and variable course. It usually starts with damage to alveolar epithelial cells in the early stage, which then develops into lung inflammation. Finally, under the stimulation of various transformation factors and inflammatory factors, various alveolar epithelial cells or lung fibroblasts are transformed into myofibroblasts. Neutrophil extracellular traps (NETs) are reticular or fibrous structures released by neutrophils that contain depolymerized chromatin filaments, myeloperoxidase (MPO) and elastase (NE). The central step in the formation of NETs is the conversion of arginine in histones to citrulline catalyzed by PAD4. Excessive NET release has a negative impact on lung diseases because NETs can easily expand in the alveoli and cause lung damage. In addition, NETs and their related molecules can directly induce epithelial and endothelial cell death. A large number of NETs have been found to be formed in several lung diseases, including asthma, chronic obstructive pulmonary disease, cystic fibrosis, respiratory syncytial virus bronchiolitis, influenza, bacterial pneumonia and tuberculosis.

[0003] The pan-PAD inhibitor chloramidine has been shown to inhibit bleomycin (BLM)-induced NETs formation in vitro and in vivo. However, chloramidine has poor inhibitory activity against PAD4 enzymes, and IC 50 is 150μM. Summary of the invention

[0004] In view of this, the object of the present invention is to provide a PAD4 inhibitor and a preparation method thereof and use thereof in the preparation of an anti-pulmonary fibrosis drug. The PAD4 inhibitor provided by the present invention has good anti-pulmonary fibrosis ability.

[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0006] The present invention provides a PAD4 inhibitor having a chemical structure shown in Formula I:

[0007]

[0008] The present invention provides a method for preparing the above-mentioned PAD4 inhibitor, comprising the following steps:

[0009] In the presence of a first condensing agent, biphenyl-3-carboxylic acid and the compound having the structure shown in Formula 1 undergo a first condensation reaction to obtain a compound having the structure shown in Formula 2;

[0010]

[0011] The compound having the structure shown in Formula 2 is subjected to a Bzl protecting group removal reaction to obtain a compound having the structure shown in Formula 3;

[0012]

[0013] In the presence of a second condensing agent, the compound having a structure represented by Formula 3 undergoes a second condensation reaction with indole-3-methylamine to obtain a compound having a structure represented by Formula 4;

[0014]

[0015] The compound having the structure shown in Formula 4 is subjected to a Boc protecting group removal reaction to obtain a compound having the structure shown in Formula 5;

[0016]

[0017] The compound having the structure shown in Formula 5 undergoes a substitution reaction with 2-chloroacetimidate ethyl ester hydrochloride to obtain a compound having the structure shown in Formula I.

[0018] Preferably, the first condensing agent and the second condensing agent include HOBt and DCC;

[0019] The first condensation reaction and the second condensation reaction are carried out under alkaline conditions; the time of the first condensation reaction and the second condensation reaction is independently 6 to 24 hours.

[0020] Preferably, the Bzl protection group removal reaction is carried out under the conditions of Pd / C catalyst and H2;

[0021] The reaction time for removing the Bzl protecting group is 12 to 36 hours.

[0022] Preferably, the deprotection reaction of the Boc protecting group is carried out in an ethyl acetate solution of HCl, and the deprotection reaction time of the Boc protecting group is 1 to 5 hours.

[0023] Preferably, the molar ratio of the compound having the structure shown in Formula 5 to ethyl 2-chloroacetimidate hydrochloride is 1:1.5-6.

[0024] Preferably, the substitution reaction time is 8 to 24 hours.

[0025] The present invention provides the use of the PAD4 inhibitor in the preparation of anti-pulmonary fibrosis drugs.

[0026] The present invention provides an anti-pulmonary fibrosis drug, comprising an active ingredient and a pharmaceutically acceptable carrier;

[0027] The active ingredient includes the above-mentioned PAD4 inhibitor.

[0028] Preferably, the dosage of the active ingredient is 1 to 10 mg / kg.

[0029] The present invention provides a PAD4 inhibitor having a structure shown in Formula I. The present invention uses PAD4 as a new target for the treatment of pulmonary fibrosis, and obtains a PAD4 inhibitor having a structure shown in Formula I by structural modification of chloramidine, which is named RC2-33. The small molecule inhibitor can inhibit PAD4 activity, reduce NETs formation, inhibit the activation and transformation of lung fibroblasts into myofibroblasts, reduce lung collagen deposition, and slow down the process of pulmonary fibrosis. The results of the embodiment show that in vitro, RC2-33 can reduce histone citrullination to inhibit NETs formation, inhibit TGF-β1-induced lung fibroblast proliferation, and downregulate interstitial marker proteins such as α-SMA, COL-I, FN-I, etc. The present invention establishes a mouse pulmonary fibrosis model induced by bleomycin (BLM), and finds that atomized inhalation of RC2-33 can effectively reduce the formation of NETs in the mouse lungs, inhibit epithelial cell to interstitial cell transformation (EMT), reduce extracellular matrix deposition (ECM), and improve mouse pulmonary fibrosis.

[0030] The present invention provides a method for preparing the PAD4 inhibitor, which is simple to operate, low in cost, and easy to realize industrialized mass production. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 A synthetic route for the PAD4 inhibitor RC2-33;

[0032] Figure 2 PAD4 inhibitor RC2-33 1 H NMR spectrum;

[0033] Figure 3 is the mass spectrum of PAD4 inhibitor RC2-33;

[0034] Figure 4 The inhibitory effects of different compounds on the release of NETs from neutrophils;

[0035] Figure 5 This is a schematic diagram of the structure of the homemade mouse oral and nasal aerosol inhalation device;

[0036] Figure 6 The weight changes of mice in each group;

[0037] Figure 7 The results of H&E staining of the lungs of mice in each group;

[0038] Figure 8 The results of Masson staining of the lungs of mice in each group. DETAILED DESCRIPTION

[0039] The present invention provides a PAD4 inhibitor having a structure shown in Formula I:

[0040]

[0041] In the present invention, the particle size of the PAD4 inhibitor having the structure shown in Formula I is preferably 180 to 260 nm, more preferably 229.9±6.3 nm.

[0042] The present invention provides a method for preparing the above-mentioned PAD4 inhibitor, comprising the following steps:

[0043] In the presence of a first condensing agent, biphenyl-3-carboxylic acid and the compound having the structure shown in Formula 1 undergo a first condensation reaction to obtain a compound having the structure shown in Formula 2;

[0044]

[0045] The compound having the structure shown in Formula 2 is subjected to a Bzl protecting group removal reaction to obtain a compound having the structure shown in Formula 3;

[0046]

[0047] In the presence of a second condensing agent, the compound having a structure represented by Formula 3 undergoes a second condensation reaction with indole-3-methylamine to obtain a compound having a structure represented by Formula 4;

[0048]

[0049] The compound having the structure shown in Formula 4 is subjected to a Boc protecting group removal reaction to obtain a compound having the structure shown in Formula 5;

[0050]

[0051] The compound having the structure shown in Formula 5 undergoes a substitution reaction with 2-chloroacetimidate ethyl ester hydrochloride to obtain a compound having the structure shown in Formula I.

[0052] In the present invention, in the presence of a first condensing agent, biphenyl-3-carboxylic acid and a compound having a structure shown in Formula 1 undergo a first condensation reaction to obtain a compound having a structure shown in Formula 2. In the present invention, the molar ratio of biphenyl-3-carboxylic acid to the compound having a structure shown in Formula 1 is preferably 1:1 to 1.5, more preferably 1:1.

[0053] In the present invention, the first condensing agent preferably includes HOBt and DCC, and the molar ratio of biphenyl-3-carboxylic acid to HOBt and DCC is preferably 1:1.05-1.4:1.05-1.5, more preferably 1:1.2:1.2.

[0054] In the present invention, the first condensation reaction is preferably carried out in an organic solvent, and the organic solvent is preferably one or more of tetrahydrofuran, dimethylformamide and acetonitrile.

[0055] In the present invention, the first condensing agent, biphenyl-3-carboxylic acid, the compound having the structure shown in Formula 1 and the organic solvent are preferably mixed in the following manner: biphenyl-3-carboxylic acid is first mixed with the organic solvent and the first condensing agent, stirred under ice bath conditions, and then the compound having the structure shown in Formula 1 is added. In the present invention, the stirring time under ice bath conditions is preferably 30 minutes.

[0056] In the present invention, the first condensation reaction is preferably carried out under alkaline conditions, and the pH value of the alkaline conditions is preferably 7 to 8. In the present invention, the alkaline agent providing the alkaline environment is preferably N-methylmorpholine.

[0057] In the present invention, the first condensation reaction is preferably carried out at room temperature under stirring, and the time of the first condensation reaction is preferably 6 to 24 hours, more preferably 8 hours.

[0058] After the first condensation reaction, the present invention preferably performs post-treatment on the obtained first condensation reaction liquid, and the post-treatment preferably comprises the following steps:

[0059] The first condensation reaction liquid is subjected to solid-liquid separation to remove the organic solvent in the liquid phase, and the residue is dissolved with ethyl acetate. The obtained dissolved product is washed, dried and concentrated to obtain a pure compound having a structure shown in Formula 2.

[0060] In the present invention, the solid-liquid separation is preferably filtration. The present invention removes dicyclohexylurea (DCU) produced during the reaction by the solid-liquid separation. In the present invention, the method of removing the organic solvent is preferably rotary evaporation. In the present invention, the washing reagents used for the washing are preferably saturated NaHCO3 aqueous solution, saturated NaCl aqueous solution, 5wt% KHSO4 aqueous solution, saturated NaCl aqueous solution, saturated NaHCO3 aqueous solution and saturated NaCl aqueous solution, and the present invention preferably uses the above-mentioned washing reagents to repeat the washing three times in sequence. In the present invention, the drying is preferably anhydrous Na2SO4 drying, and after the drying, it is preferably to remove Na2SO4 by vacuum filtration. In the present invention, the concentration is preferably concentrated under reduced pressure.

[0061] After obtaining the compound having the structure shown in Formula 2, the compound having the structure shown in Formula 2 is subjected to a Bzl protection group removal reaction to obtain a compound having the structure shown in Formula 3. In the present invention, the Bzl protection group removal reaction is preferably carried out under conditions containing a Pd / C catalyst and H2; the mass of the Pd / C catalyst is preferably 5 to 15% of the mass of the compound having the structure shown in Formula 2, and more preferably 10%.

[0062] In the present invention, the Bzl protecting group removal reaction is preferably carried out in an organic solvent, and the organic solvent is preferably methanol, ethanol, acetonitrile and dioxane.

[0063] In the present invention, the Bzl deprotection reaction is preferably carried out at room temperature with stirring; the Bzl deprotection reaction time is preferably 12 to 36 hours, more preferably 24 hours.

[0064] After the Bzl protection group removal reaction, the present invention preferably performs post-treatment on the obtained Bzl protection group removal reaction solution, and the post-treatment preferably includes the following steps:

[0065] The Bzl protection group removal reaction solution is subjected to solid-liquid separation, and the obtained liquid phase is concentrated to obtain a pure compound having a structure shown in Formula 3.

[0066] In the present invention, the solid-liquid separation method is preferably vacuum filtration, and the present invention removes the Pd / C catalyst through the solid-liquid separation. In the present invention, the concentration is preferably vacuum concentration to dryness.

[0067] After obtaining the compound having the structure shown in Formula 3, the compound having the structure shown in Formula 3 and indole-3-methylamine undergo a second condensation reaction in the presence of a second condensing agent to obtain a compound having the structure shown in Formula 4. In the present invention, the molar ratio of the compound having the structure shown in Formula 3 to indole-3-methylamine is preferably 1:1.

[0068] In the present invention, the second condensing agent preferably includes HOBt and DCC, and the molar ratio of the compound having the structure represented by Formula 3 to HOBt and DCC is preferably 1:1.05-1.4:1.05-1.5, and more preferably 1:1.2:1.2.

[0069] In the present invention, the second condensation reaction is preferably carried out in an organic solvent, and the organic solvent is preferably one or more of tetrahydrofuran, dimethylformamide and acetonitrile.

[0070] In the present invention, the second condensing agent, the compound having the structure shown in Formula 3, indole-3-methylamine and the organic solvent are preferably mixed in the following manner: the compound having the structure shown in Formula 3 is first mixed with the organic solvent and the condensing agent, stirred under ice bath conditions, and then indole-3-methylamine is added. In the present invention, the stirring time under ice bath conditions is preferably 30 minutes.

[0071] In the present invention, the second condensation reaction is preferably carried out under alkaline conditions, and the pH value of the alkaline conditions is preferably 7 to 8. In the present invention, the alkaline agent providing the alkaline environment is preferably N-methylmorpholine.

[0072] In the present invention, the second condensation reaction is preferably carried out at room temperature with stirring, and the time of the second condensation reaction is preferably 6 to 24 hours, more preferably 8 hours.

[0073] After the second condensation reaction, the present invention preferably performs post-treatment on the obtained second condensation reaction liquid, and the post-treatment preferably includes the following steps:

[0074] The second condensation reaction liquid is subjected to solid-liquid separation to remove the organic solvent in the liquid phase, and the residue is dissolved with ethyl acetate. The obtained dissolved product is washed, dried and concentrated to obtain a pure compound having a structure shown in Formula 4.

[0075] In the present invention, the solid-liquid separation is preferably filtration. In the present invention, the method for removing the organic solvent is preferably rotary evaporation. In the present invention, the washing reagents used in the washing are preferably saturated NaHCO3 aqueous solution, saturated NaCl aqueous solution, 5wt% KHSO4 aqueous solution, saturated NaCl aqueous solution, saturated NaHCO3 aqueous solution and saturated NaCl aqueous solution, and the present invention preferably uses the above-mentioned washing reagents to repeat washing three times in sequence. In the present invention, the drying is preferably anhydrous Na2SO4 drying, and after the drying, it is preferably to remove Na2SO4 by vacuum filtration. In the present invention, the concentration is preferably reduced pressure concentration.

[0076] After obtaining the compound having the structure shown in Formula 4, the compound having the structure shown in Formula 4 is subjected to a Boc protection group removal reaction to obtain a compound having the structure shown in Formula 5. In the present invention, the Boc protection group removal reaction is preferably carried out in an ethyl acetate solution of HCl, and the concentration of HCl in the ethyl acetate solution of HCl is preferably 2 to 5 mol / L, more preferably 4 mol / L. In the present invention, the Boc protection group removal reaction is preferably carried out under ice bath conditions, and the time for the Boc protection group removal reaction is preferably 1 to 5 hours, more preferably 4 hours.

[0077] After the Boc protection group removal reaction, the present invention preferably performs post-treatment on the obtained Boc protection group removal reaction solution, and the post-treatment preferably includes the following steps:

[0078] The Boc protection group removal reaction solution was drained, and the obtained residue was added with dry ethyl acetate, and the process of draining and adding dry ethyl acetate was repeated 3 times, and finally drained to obtain a drained residue;

[0079] Dry petroleum ether was added to the obtained drained residue, and the mixture was drained. The process of adding dry petroleum ether and draining was repeated three times to obtain a pure compound having the structure shown in Formula 5.

[0080] After obtaining the compound having the structure shown in Formula 5, the compound having the structure shown in Formula 5 is subjected to a substitution reaction with 2-chloroacetimidate ethyl ester hydrochloride to obtain a compound having the structure shown in Formula I. In the present invention, the molar ratio of the compound having the structure shown in Formula 5 to 2-chloroacetimidate ethyl ester hydrochloride is preferably 1:5.

[0081] In the present invention, the substitution reaction is preferably carried out in an organic solvent, and the organic solvent is preferably one or more of methanol, ethanol and acetonitrile.

[0082] In the present invention, the compound having the structure shown in Formula 5, 2-chloroacetimidate ethyl hydrochloride and the organic solvent are preferably mixed in the following manner: the compound having the structure shown in Formula 5 is first mixed with the organic solvent, and 2-chloroacetimidate ethyl hydrochloride is added under ice bath conditions.

[0083] In the present invention, the substitution reaction is preferably carried out under alkaline conditions, and the alkaline pH value is preferably 10. In the present invention, the alkaline agent used to adjust the pH value is preferably N,N-diisopropylethylamine (DIPEA).

[0084] In the present invention, the substitution reaction is preferably carried out at room temperature with stirring; the substitution reaction time is preferably 8 to 24 hours, more preferably 12 hours.

[0085] After the substitution reaction, the present invention preferably performs post-treatment on the obtained substitution reaction solution, and the post-treatment preferably comprises the following steps:

[0086] The substitution reaction solution is concentrated, and the obtained concentrated solution is dissolved in water and purified by C18 column chromatography to obtain a pure product of the compound with the structure shown in Formula I.

[0087] In the present invention, the concentration is preferably reduced pressure concentration, and the conditions for the C18 column chromatography purification include methanol: dichloromethane: acetic acid = 1: 5-15: 0.1-0.5.

[0088] The present invention provides the use of the PAD4 inhibitor in the preparation of anti-pulmonary fibrosis drugs.

[0089] The present invention provides an anti-pulmonary fibrosis drug, comprising an active ingredient and a pharmaceutically acceptable carrier. The present invention has no special requirements for the carrier, and a pharmaceutically acceptable carrier well known in the art can be used. In the present invention, the carrier is preferably one or more of lipid nanoparticles, lipid-polymer hybrid nanoparticles, nanostructured lipid carriers and cationic polymers.

[0090] The active ingredients include the above-mentioned anti-pulmonary fibrosis drugs.

[0091] In the present invention, the dosage form of the anti-pulmonary fibrosis drug is preferably an aerosol.

[0092] In the present invention, the dosage of the active ingredient is preferably 1 to 10 mg / kg.

[0093] The PAD4 inhibitor provided by the present invention, its preparation method and its application in the preparation of anti-pulmonary fibrosis drugs are described in detail below in conjunction with the examples, but they should not be construed as limiting the scope of protection of the present invention.

[0094] Example 1 Synthesis of PAD4 inhibitor RC2-33

[0095] according to Figure 1 The PAD4 inhibitor RC2-33 was synthesized by the following route:

[0096] 1) Preparation of (S)-2-([1,1'-biphenyl]-3-formamido)-5-((tert-butyloxycarbonyl)amino)pentanoic acid benzyl ester:

[0097] Dissolve 10mmol of biphenyl-3-carboxylic acid in 20mL of anhydrous tetrahydrofuran (THF), add 12mmol of N-hydroxybenzotriazole (HOBt) and dissolve it completely, slowly add 12mmol of dicyclohexylcarbodiimide (DCC), stir for 30min under ice bath, then add 10mmol of (S)-2-amino-5-((tert-butoxycarbonyl)amino)pentanoic acid benzyl ester hydrochloride to the reaction solution, dropwise add N-methylmorpholine (NMM), and adjust the pH value to 7-8. Stir at room temperature for 8h, TLC (dichloromethane: methanol = 25:1) shows that the raw material disappears. Filter to remove dicyclohexylurea (DCU), and remove THF by rotary evaporation. The residue was dissolved with 20 mL of ethyl acetate (EA), and the resulting solution was washed three times with saturated aqueous NaHCO3 solution, saturated aqueous NaCl solution, 5% aqueous KHSO4 solution, saturated aqueous NaCl solution, saturated aqueous NaHCO3 solution, and saturated aqueous NaCl solution, respectively. The ethyl acetate layer was dried over anhydrous Na2SO4, and Na2SO4 was removed by filtration under reduced pressure. The filtrate was concentrated to dryness under reduced pressure to obtain compound (S)-2-([1,1'-biphenyl]-3-formamido)-5-((tert-butyloxycarbonyl)amino)pentanoic acid benzyl ester.

[0098] ESI-MS (m / z): 503.31 [M+H] + . 1 H NMR (500MHz, DMSO-d6) δ8.87(d,J=7.5Hz,1H),8.14(t,J=1.9Hz,1H),7.84(ddt,J=17.3,7.8,1.4Hz ,2H),7.74-7.68(m,2H),7.56(t,J=7.7Hz,1H),7.49(dd,J=8.4,7.0Hz,2H),7.43-7.36(m,1H),7.34 (dddd,J=11.5,7.3,5.9,1.7Hz,4H),7.33-7.25(m,1H),6.78(t,J=5.6Hz,1H),5.15(s,2H),4.53(dd d,J=9.8,7.3,5.0Hz,1H),2.95(q,J=6.5Hz,2H),1.93-1.74(m,2H),1.60-1.43(m,2H),1.34(s,9H).

[0099] 2) Preparation of (S)-2-([1,1'-biphenyl]-3-formamido)-5-((tert-butyloxycarbonyl)amino)pentanoic acid:

[0100] 10mmol (S)-2-([1,1'-biphenyl]-3-formylamino)-5-((tert-butyloxycarbonyl)amino)pentanoic acid benzyl ester was stirred and dissolved with an appropriate amount of methanol, and 10wt% Pd / C was added. The reaction system was kept closed, and the air was evacuated with a three-way valve, and hydrogen was connected, and then the three-way valve was used to evacuate the air in the reaction system. The hydrogen environment was kept and stirred at room temperature for 24 hours. TLC (dichloromethane: methanol = 20:1) monitored the disappearance of the raw material point. Pd / C was removed by vacuum filtration, and the filtrate was concentrated to dryness under reduced pressure to obtain (S)-2-([1,1'-biphenyl]-3-formylamino)-5-((tert-butyloxycarbonyl)amino)pentanoic acid. ESI-MS (m / z): 411.89 [MH] - .

[0101] 3) Preparation of tert-butyl (S)-(5-(((1H-indol-3-yl)methyl)amino)-4-([1,1'-biphenyl]-3-formamido)-5-oxopentyl)carbamate:

[0102] Dissolve 10mmol (S)-2-([1,1'-biphenyl]-3-carboxamido)-5-((tert-butyloxycarbonyl)amino)pentanoic acid in 20mL anhydrous tetrahydrofuran (THF), add 12mmol N-hydroxybenzotriazole (HOBt) 12mmol and dicyclohexylcarbodiimide (DCC), stir for 30min under ice bath, then add 10mmol indole-3-methylamine to the reaction solution, add N-methylmorpholine (NMM) dropwise, adjust the pH value to 7-8, stir at room temperature for 8h, TLC (dichloromethane: methanol = 20:1) shows that benzoic acid disappears. Filter off dicyclohexylurea (DCU), and remove THF by rotary evaporation. The residue was dissolved in 20 mL of ethyl acetate (EA), and the resulting solution was washed three times with saturated aqueous NaHCO3 solution, saturated aqueous NaCl solution, 5% aqueous KHSO4 solution, saturated aqueous NaCl solution, saturated aqueous NaHCO3 solution, and saturated aqueous NaCl solution. The ethyl acetate layer was dried over anhydrous Na2SO4, and the desiccant was removed by filtration under reduced pressure. The filtrate was concentrated to dryness under reduced pressure to obtain compound (S)-tert-butyl (5-(((1H-indol-3-yl)methyl)amino)-4-([1,1'-biphenyl]-3-formamido)-5-oxopentyl)carbamate.

[0103] ESI-MS (m / z): 541.35 [M+H] + . 1 H NMR(300MHz,DMSO-d6)δ10.92(d,J=

[0104] 2.5Hz,1H),8.61(d,J=8.1Hz,1H),8.28-8.14(m,2H),7.85(ddt,J=15.6,7.8,1.3Hz,2H),7 .79-7.69(m,2H),7.62-7.46(m,4H),7.46-7.30(m,2H),7.25(d,J=2.4Hz,1H),7.07(ddd,J= 8.2,7.0,1.2Hz,1H),6.95(ddd,J=7.9,7.0,1.1Hz,1H),6.79(t,J=5.6Hz,1H),5.76(s,0H), 4.47(dd,J=15.7,5.4Hz,3H),2.92(q,J=6.5Hz,2H),1.74(s,2H),1.47(s,2H),1.35(s,9H).

[0105] 4) Preparation of (S)-N-(1-(((1H-indol-3-yl)methyl)amino)-5-amino-1-oxopentan-2-yl)-[1,1'-biphenyl]-3-carboxamide:

[0106] 4N HCl / EtOAc solution was added to tert-butyl (S)-(5-(((1H-indol-3-yl)methyl)amino)-4-([1,1'-biphenyl]-3-carboxamido)-5-oxopentyl)carbamate in an ice bath, and the reaction was stirred for 4 hours. TLC (DCM:MeOH:HAc=25:1:2d) showed that the raw material point disappeared, and ninhydrin showed purple at the origin. The solution was pumped dry with a circulating water pump, and dry ethyl acetate was added. The reaction solution was pumped dry again with a water pump, and the reaction mixture was repeated three times. Dry petroleum ether was added, and the reaction mixture was pumped dry with a water pump, and the reaction mixture was repeated three times to obtain compound (S)-N-(1-(((1H-indol-3-yl)methyl)amino)-5-amino-1-oxopentyl-2-yl)-[1,1'-biphenyl]-3-carboxamide. ESI-MS (m / z): 441.31 [M+H] + .

[0107] 5) Preparation of (S)-N-(1-(((1H-indol-3-yl)methyl)amino)-5-(2-chloroacetylamidino)-1-oxopentan-2-yl)-[1,1'-biphenyl]-3-carboxamide (RC2-33):

[0108] 1mmol (S)-N-(1-(((1H-indol-3-yl)methyl)amino)-5-amino-1-oxopentan-2-yl)-[1,1'-biphenyl]-3-carboxamide was dissolved by stirring with an appropriate amount of anhydrous methanol. 5mmol 2-chloroacetimidate ethyl ester hydrochloride was added under ice-water bath, and the pH value was adjusted to 10 with N,N-diisopropylethylamine (DIPEA). Stir at room temperature for 12h. TLC (EA:H2O:HAc=4:1:1) showed that the raw material point disappeared. The mixture was concentrated to dryness under reduced pressure, dissolved in ultrapure water, and purified by C18 column chromatography to obtain the target product RC2-33.

[0109] ESI-MS (m / z): 516.17 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ10.95(d,J=2.5Hz,1H),9.60(s,1H),9.17(s,1H),8.74(d,J=8.1Hz,1H),8.36(t,J=5.5Hz,1H ),8.21(d,J=1.9Hz,1H),7.91(dt,J=7.7,1.4Hz,1H),7.84(dt,J=7.8,1.4Hz,1H),7.80-7.70(m,2H),7.62-7.46(m,4 H),7.46-7.30(m,2H),7.25(d,J=2.4Hz,1H),7.06(ddd,J=8.1,6.9,1.2Hz,1H),6.94(ddd,J=7.9,7.0,1.1Hz,1H),4. 56(dt,J=8.5,4.3Hz,1H),4.55-4.38(m,4H),3.27(t,J=6.5Hz,2H),1.91-1.76(m,2H),1.64(dq,J=15.7,8.0Hz,2H).

[0110] The obtained PAD4 inhibitor RC2-33 1 H NMR spectrum (300 MHz, DMSO-d6) Figure 2 shown.

[0111] The mass spectrum of the obtained PAD4 inhibitor RC2-33 is as follows Figure 3 shown.

[0112] The melting point, particle size and Zeta potential of the obtained PAD4 inhibitor are shown in Table 1. The particle size was tested using a nanoparticle size analyzer (Nano-ZS90, Malvern, UK); the Zeta potential was tested using a Zeta potential instrument; and the melting point was tested using a melting point instrument (Shanghai Shenguang WRR visual melting point instrument).

[0113] Table 1 Melting point, particle size and Zeta potential of PAD4 inhibitor RC2-33

[0114] Compound Melting point(℃) Particle size (nm) Zeta potential (mV) RC2-33 132.4~133.9 229.9±6.3 12.3±0.4

[0115] As can be seen from Table 1, the nanoparticle size distribution of RC2-33 is reasonable, which can reduce the influence of gas shear force (<250nm) and is suitable for inhalation administration.

[0116] Test Example 1 In vitro evaluation of anti-pulmonary fibrosis

[0117] 1. Anti-proliferation of lung fibroblasts

[0118] HLF (human lung fibroblast) cells were seeded in a 96-well plate at 5000 cells per well, cultured overnight in F12K medium supplemented with 10% FBS, and then different concentrations of compounds were added for co-incubation for 24 h. 5 mg / mL of MTT was added and incubated for another 4 h. The absorbance at 490 and 570 nm was measured using a multifunctional microplate reader. BEAS-2B (human lung epithelial cells) were treated in the same way, and the data were analyzed by one-way ANOVA using Graphpad Prism 9.4.0 software. The results are shown in Table 2.

[0119] Table 2 IC of the in vitro anti-cell proliferation activity of the tested compounds against HLF and BEAS-2B 50 value

[0120]

[0121] As shown in Table 2, compound RC2-33 inhibited the proliferation of HLF and BEAS-2B cells in a dose-dependent manner within the concentration range of 0 to 100 μM. 50 It is 12.44±1.19.

[0122] 2. Anti-migration of lung fibroblasts

[0123] 50,000 HLF cells suspended in serum-free F12K medium were inoculated in the upper chamber of the transwell. 600 μL of medium containing 10% fetal bovine serum and TGF-β1 (5 ng / mL) was added to the chamber. Then they were divided into 1) Control group (no treatment), 2) RC2-33 group. After adding 5 μM of drug to the upper chamber and incubating for 24 hours, the upper chamber liquid was aspirated, and the cells were fixed with 4% paraformaldehyde at 4°C for 30 minutes and stained with crystal violet at room temperature for 15 minutes. The crystal violet was washed off, and the unmigrated cells on the upper membrane were wiped off with a cotton swab. After drying, the cells were photographed with an optical microscope (Zeiss, Germany). The migration rate was expressed as area, expressed as Mean±SD, and the results are shown in Table 3.

[0124] Table 3 In vitro anti-HLF metastasis activity of the tested compounds

[0125] Group Dosage (μM) Relative mobility (%) Control / 100±8.45 RC2-33 5 50.83±6.31****

[0126] In Table 3, compared with the Control group, ****p<0.0001.

[0127] As shown in Table 3, compared with the Control group without any treatment, the number of cells passing through the Transwell chamber membrane in the group treated with compound RC2-33 was significantly reduced, indicating that compound RC2-33 can inhibit the activity of TGF-β1-induced HLF cell migration in vitro.

[0128] 3. Inhibit pulmonary fibroblast activation

[0129] HLF cells were cultured at 5×10 5 The cells were inoculated in a confocal dish, cultured overnight in F12K medium supplemented with 10% FBS, and then replaced with serum-free medium for starvation for 12 h. 5 μM drugs were added for incubation for 12 h, and then TGF-β1 (5 ng / mL) was added. After incubation for 48 h, the medium was removed, fixed with 4% paraformaldehyde for 30 min at 4°C, washed with PBST and PBS, respectively, and blocked with 5% BSA for 30 min. Rabbit polyclonal antibodies against smooth actin (α-SMA), fibronectin (FN-I) and collagen (COL1) were added, and incubated overnight at 4°C. After washing with PBST and PBS again, goat anti-rabbit secondary antibodies labeled with AlexaFluor488 and AlexaFluor568 were added, respectively, and incubated in the dark at room temperature for 2 h. After washing with PBST and PBS, the nuclei were stained with DAPI for 3 min, and then washed with PBST and PBS, anti-fluorescence quenching sealing medium was added. The cells were analyzed using a laser confocal microscope (TCS SP8STED, Leica, Germany) was used to observe and take pictures, and the average fluorescence intensity was analyzed using Image J. Protein expression was expressed as mean fluorescence intensity (Mean±SD), and the results are shown in Table 4. RC2-33 was also processed and tested using the same method.

[0130] Table 4 Inhibitory effect of the tested compounds on TGF-β-induced HLF fibrosis

[0131] Group α-SMA FN-I COL1 Control 6.20±1.45 25.41±5.23 7.66±0.86 TGF-β1 31.34±5.70 68.31±6.99 44.12±1.83 RC2-33 16.48±1.54**** 20.66±5.29**** 8.12±1.23****

[0132] In Table 4, compared with the TGF-β1 group, ****p<0.0001.

[0133] As shown in Table 4, compared with the Control group without any treatment, the expression of fibrosis marker proteins α-SMA, FN-I, and COL1 in HLF cells treated with TGF-β1 increased, while compound RC2-33 treatment could downregulate the expression of these fibrosis marker proteins, indicating that compound RC2-33 could inhibit the fibrosis of HLF cells.

[0134] 4. Inhibition of NETs release from neutrophils in vitro

[0135] After killing ICR mice by dislocation of the neck, the hind legs were removed, the bone ends were cut to expose the cavity, and the bone marrow suspension was washed out with PBS. The bone marrow single cell suspension was filtered through a 70 μm nylon filter. Neutrophils were isolated using a mouse neutrophil isolation kit (TBDSceicge, LZS1100) and inoculated into confocal microplates, with 5×10 cells per dish. 5 The compound 5 μM RC2-33 was immediately added for incubation for 2 hours, and then 5 μmol / L calcium ion carrier A23187 was added for induction for 2 hours, and then the medium was removed by centrifugation, washed with PBST and PBS, fixed with 4% paraformaldehyde for 15 minutes, washed with PBST and PBS, blocked with 5% BSA for 30 minutes, washed with PBST and PBS, and added with H3cit antibody (ABCAM: ab5103) at 4°C overnight. The primary antibody was recovered by centrifugation, washed with PBST and PBS, and stained with DAPI for 3 minutes. After washing with PBST and PBS, anti-fluorescence quenching sealing agent was added, and observed using a Leica STED super-resolution confocal microscope (TCS SP8 STED, Leica, Germany).

[0136] The inhibitory effect of compounds on NETs release from neutrophils Figure 4 As shown. It can be seen that after induction with phorbol ester (PMA), neutrophils release filaments composed of DNA (blue fluorescence) and H3cit (red), which are neutrophil extracellular traps (NETs). In comparison, after treatment with compound RC2-33, this filament is significantly reduced and the red fluorescence intensity is weakened, indicating that compound RC2-33 can inhibit the release of NETs by neutrophils. Scanning electron microscopy also proves this result.

[0137] Test Example 2 Evaluation of in vivo anti-fibrotic activity

[0138] 1. Experimental Methods

[0139] Male C57 / BL6 mice were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. All animal experiments were performed in accordance with the protocols approved by the Animal Care and Use Committee of Capital Medical University. Mice were randomly divided into 1) Normal (n = 6), 2) Model (n = 10), 3) Compound RC2-33 group (5 mg / kg, n = 10), 4) Positive drug pirfenidone group (PFD) (100 mg / kg, n = 10). After 3 days of adaptive feeding, the mice were anesthetized with isoflurane, and bleomycin (BLM, 5 mg / kg) was instilled intratracheally to induce a mouse pulmonary fibrosis model except for the Normal group. Ten days after the instillation, the mice were treated with the following: Figure 5 The homemade mouse oral and nasal atomizer inhalation device shown was used to give drug treatment. The Model group was given normal saline, and the compound group was given the compound according to the body weight dose, and the drug was given continuously for 10 days. The weight of the mice was recorded at intervals. After the experiment, the lungs of the mice were taken out and the ratio of lung weight to body weight was weighed as the lung coefficient. Blood was taken from the eyeballs of the mice and centrifuged to obtain serum for ELISA kit detection of various inflammatory factors and fibrosis markers; lung tissue was fixed and sliced ​​for HE and Masson staining, and the degree of fibrosis was scored according to the ASHCROFT rule; lung slices were also immunohistochemically examined for the expression of fibrosis-related proteins.

[0140] 2. Statistical methods

[0141] The data were expressed as mean ± standard deviation (x ± s) and statistically analyzed using Graphpadprism software. One-way analysis of variance (ANOVA) was used for comparison among multiple groups. p < 0.05 indicated a statistically significant difference.

[0142] 3. Results and Analysis

[0143] 3.1 Effects of compounds on body weight of mice with pulmonary fibrosis

[0144] The body weight of mice in each group was weighed and recorded before modeling by intratracheal instillation of bleomycin (BLM) and 7, 14, and 21 days after modeling. The body weight of mice generally decreases rapidly after pulmonary fibrosis.

[0145] The weight changes of mice in each group were as follows Figure 6 As shown. It can be seen that the weight of mice in the Normal group increased steadily, while the weight of mice in the Model group dropped sharply 7 days after modeling. The weight of other groups decreased within 7 days of modeling, which is also an argument for the establishment of the model. After the start of drug treatment, the weight of mice in the positive control PFD group and the compound RC2-33 group began to recover. The weight of the compound RC2-33 group had returned to the level before modeling on the 21st day. The above shows that RC2-33 is beneficial to the recovery of the physical condition of mice with pulmonary fibrosis.

[0146] 3.2 Effects of compounds on lung coefficients in mice with pulmonary fibrosis

[0147] The lungs of mice in each group were taken out and weighed, and the lung coefficient was calculated according to the following formula: lung coefficient = lung weight (mg) / body weight (g). Because a large number of inflammatory cells infiltrate in the early stage of pulmonary fibrosis, the number of fibroblasts increases in the late stage, collagen deposition increases, and extracellular matrix (ECM) is formed in the lungs, which increases the lung weight and the lung coefficient. The lung weight, body weight and lung coefficient of mice in each group are shown in Table 5.

[0148] Table 5 Lung weight, body weight and lung coefficient of mice in each group

[0149] Group Lung weight (mg) Weight (g) Lung coefficient (mg / g) Normal 147.75±11.85 21.72±0.50 6.80±0.46 Model 235.14±19.74 15.11±1.65 15.78±2.36 PFD 152.18±33.5 20.36±2.64 7.77±2.76**** RC2-33 200.08±39.43 20.33±1.34 9.90±2.11****

[0150] In Table 5, compared with the Model group, ***p<0.001, ****p<0.0001.

[0151] 3.3 Effects of compounds on lung tissue morphology in mice with pulmonary fibrosis

[0152] The lungs of mice in each group were removed, fixed with tissue fixative, and then embedded in paraffin and sectioned for H&E and Masson staining. Figure 7 , Figure 8 and as shown in Table 6.

[0153] Table 6 Effects of compound RC2-33 on BLM-induced pulmonary fibrosis in mice

[0154] Group Dosage (mg / kg) Ashcroft Scoring Normal / 0.54±0.18 Model / 4.29±0.58 PFD 100 2.30±0.42*** RC2-33 5 2.57±0.64***

[0155] In Table 6, compared with the Model group, ***p<0.001.

[0156] It can be seen that the lung tissue structure of the mice in the Normal group was clear, the alveoli were intact, the alveolar cavities were large and abundant, and the alveolar septa were not thickened. After BLM induction, the lung structure of the mice in the Model group changed, which was specifically manifested by the thickening of the alveolar wall, the narrowing or even disappearance of the alveolar cavity, and severe inflammatory infiltration. Masson staining showed a large amount of fibrosis and collagen deposition in the pulmonary interstitium (p<0.0001). The lung tissue structure of the mice in the positive drug PFD group and RC2-33 group was significantly improved (p<0.001), and the alveolar structure was restored, which shows that compound RC2-33 can improve BLM-induced pulmonary fibrosis in mice.

[0157] 3.4 Effects of compounds on serum-related factors in mice with pulmonary fibrosis

[0158] Blood was collected from the eyeballs of mice and placed at room temperature for 2 hours. The blood was then centrifuged at 3000 rpm for 10 minutes. The supernatant was removed and the contents of SP-A, Hyp, KL-6, TNF-α, IL-17A and MMP-7 factors were detected using ELISA kits. The results are shown in Table 7.

[0159] Table 7 Effects of compounds on the expression of fibrosis-related factors in the serum of mice with pulmonary fibrosis

[0160] Normal Model PFD RC2-33 SP-A 86.19±15.70 <![CDATA[155.73±14.89 #### ]]> 98.94±8.57 102.98±4.66**** Hyp 84.56±7.75 <![CDATA[143.56±11.16 #### ]]> 103.14±4.56 115.49±4.65**** KL-6 4.16±0.26 <![CDATA[6.23±0.38 #### ]]> 4.60±0.33 4.58±0.37**** TNF-α 273.68±12.13 <![CDATA[682.68±35.81 #### ]]> 426.32±60.88 527.21±7.15**** IL-17A 9.58±0.72 <![CDATA[31.32±3.05 #### ]]> 16.01±1.13 19.59±2.02**** MMP-7 31.47±1.85 <![CDATA[47.29±2.38 #### ]]> 31.53±2.33 34.51±1.61****

[0161] In Table 7, compared with the Normal group, #### p<0.0001, compared with the Model group, **p<0.01, ****p<0.0001.

[0162] It can be seen that compared with the Normal group mice, the levels of SP-A, Hyp, KL-6, TNF-α, IL-17A and MMP-7 in the serum of mice with BLM-induced pulmonary fibrosis increased, which indicates that the inflammatory response of mice with pulmonary fibrosis increased and collagen was deposited in large quantities. Compared with the Model group, the levels of related factors in the serum of the RC2-33 group decreased, and the difference was statistically significant.

[0163] In summary, the PAD4 inhibitor RC2-33 provided by the present invention has good anti-pulmonary fibrosis ability.

[0164] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A PAD4 inhibitor having a chemical structure shown in Formula I:

2. The method for preparing the PAD4 inhibitor according to claim 1, comprising the following steps: In the presence of a first condensing agent, biphenyl-3-carboxylic acid and the compound having the structure shown in Formula 1 undergo a first condensation reaction to obtain a compound having the structure shown in Formula 2; The compound having the structure shown in Formula 2 is subjected to a Bzl protecting group removal reaction to obtain a compound having the structure shown in Formula 3; In the presence of a second condensing agent, the compound having a structure represented by Formula 3 undergoes a second condensation reaction with indole-3-methylamine to obtain a compound having a structure represented by Formula 4; The compound having the structure shown in Formula 4 is subjected to a Boc protecting group removal reaction to obtain a compound having the structure shown in Formula 5; The compound having the structure shown in Formula 5 undergoes a substitution reaction with 2-chloroacetimidate ethyl ester hydrochloride to obtain a compound having the structure shown in Formula I.

3. The preparation method according to claim 2, characterized in that: The first condensing agent and the second condensing agent include HOBt and DCC; The first condensation reaction and the second condensation reaction are carried out under alkaline conditions; the time of the first condensation reaction and the second condensation reaction is independently 6 to 24 hours.

4. The preparation method according to claim 2, characterized in that: The Bzl protection group removal reaction is carried out under the conditions of Pd / C catalyst and H2; The reaction time for removing the Bzl protecting group is 12 to 36 hours.

5. The preparation method according to claim 2, characterized in that: The deprotection reaction of the Boc protecting group is carried out in an ethyl acetate solution of HCl, and the deprotection reaction time of the Boc protecting group is 1 to 5 hours.

6. The preparation method according to claim 2, characterized in that: The molar ratio of the compound having the structure shown in Formula 5 to ethyl 2-chloroacetimidate hydrochloride is 1:1.5-6.

7. The preparation method according to claim 2 or 6, characterized in that: The substitution reaction time is 8 to 24 hours.

8. Use of the PAD4 inhibitor according to claim 1 in the preparation of anti-pulmonary fibrosis drugs.

9. An anti-pulmonary fibrosis drug comprising an active ingredient and a pharmaceutically acceptable carrier; The active ingredient comprises the PAD4 inhibitor according to claim 1.

10. The anti-pulmonary fibrosis drug according to claim 9, characterized in that: The dosage of the active ingredient is 1 to 10 mg / kg.

Citation Information

Patent Citations

  • Arginine derivatives

    CN1535264A

  • Endothelin receptor antagonists

    WO1995012611A1

Cited By

  • Temperature-sensitive PAD4 inhibitor loaded hydrogel as well as preparation method and application thereof

    CN120713832A